OsteoporeASX:OSX +11.11% EV-to-EBIT is -1.61 as of Jul. 12, 2026. The stock has 7 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Osteopore ranks worse than 214132.55% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Osteopore's Enterprise Value for the quarter that ended in Dec. 2025 was A$3.91 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Osteopore's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Osteopore EV-to-EBIT Related Terms
Osteopore EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Osteopore's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Osteopore's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Osteopore EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Osteopore's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Osteopore's EV-to-EBIT falls into.
Osteopore's current Enterprise Value is A$5.53 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Osteopore's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Osteopore (ASX:OSX) has a EV-to-EBIT of -1.61 as of Jul. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Osteopore and its competitors. According to the industry distribution chart, Osteopore ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Osteopore's EV-to-EBIT too high?
Osteopore's current EV-to-EBIT is -1.61. Based on the distribution chart, Osteopore ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Osteopore's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Osteopore ranks #999999 out of 467 companies for EV-to-EBIT. This places Osteopore in the lower half of its industry. The industry median EV-to-EBIT is 18.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.49, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Osteopore and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Osteopore's current EV-to-EBIT is -1.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Osteopore stock overvalued right now?
Based on GuruFocus' analysis, Osteopore (ASX:OSX) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 75% below its estimated fair value. The current EV-to-EBIT is -1.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Osteopore (ASX:OSX), the current EV-to-EBIT is -1.61 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. It operate in the high-growth regenerative medicine sector, where adoption continues to rise as healthcare systems increasingly embrace developed tissue-regenerative solutions. Business operating segments are based on the firm's geographical presence in Singapore and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSX has been successfully added to your 